• Press Release

Novel COVID-19 Antibody Therapy Candidates Identified by Leading UK Biotech Consortium

• Potent antibody drug combinations identified • Candidate antibodies could be used to treat and protect against SARSCoV-2 infections • Antibody combinations differentiated from others currently being investigated

Record quarter for UK biotech as £1bn is raised

New data published today by the BioIndustry Association (BIA) and Clarivate reveals that UK biotech companies raised more than £1billion in equity finance between June and August 2020, the highest quarter for investments in the sector on record.

BIA responds to Health Secretary announcement that the MHRA will join Project Orbis

The Health Secretary, Matt Hancock MP, has announced today in the House of Commons that the MHRA (the UK medicine regulator) will join Project Orbis, an initiative led by the USA’s Food and Drug Administration Oncology Centre of Excellence. 

BioIndustry Association responds to the publication of the United Kingdom Internal Market Bill

Steve Bates OBE, Chief Executive of the BioIndustry Association said: “The BIA welcomes the commitment in the Bill to preserve the UK internal market, aimed at providing certainty for businesses to work and trade freely across the whole of the UK.

Investing in UK biotech has never been more attractive

Biotech stocks have never been a more attractive destination for investors. As traditional sectors continue to suffer with the market disruption brought about by COVID-19, biopharma and healthcare is one of the few economic sectors to have largely escaped the global downturn.

BIA responds to launch of the National Institute for Health Protection (NIHP)

Commenting on the launch of the National Institute for Health Protection (NIHP) Steve Bates OBE, Chief Executive of the U.K. Bioindustry Association said: 

£30 million Biomedical Catalyst opens for applications following successful BIA campaign

From today, innovative biotech companies will be able to apply for access to a share of £30 million in grant funding through a relaunched Biomedical Catalyst.

Government announces funding for scale up of COVID-19 vaccine with additional investment to support upskilling in Cell and Gene Therapy and Vaccine manufacturing

Today the Department of Business, Energy and Industrial Strategy has awarded £100 million to fund a Cell and Gene Therapy Catapult Manufacturing Innovation Centre to accelerate production of a COVID-19 vaccine in the UK.

BIA welcomes Global AMR Action Fund to tackle antimicrobial resistance 

Steve Bates OBE, Chief Executive of the BIA said: “Antimicrobial resistance (AMR) is one of the key global challenges of our times. Despite being a global health (and BIA) policy focus for years, no market solution has yet delivered the incentives needed to make novel antibiotic development an attractive investment prospect.

BIA welcomes new deal between Vertex and NHS England 

Steve Bates OBE, Chief Executive of the BIA said: “It’s fantastic to see the NHS and Vertex strike a lightning quick deal to enable NHS cystic fibrosis patients to access this important breakthrough therapy.